Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

Abdallah A Ellabban, Akitaka Tsujikawa, Ken Ogino, Sotaro Ooto, Kenji Yamashiro, Akio Oishi, Nagahisa YoshimuraDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanPurpose: To study changes in choroidal thickness with ranibizumab treatment for ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ellabban AA, Tsujikawa A, Ogino K, Ooto S, Yamashiro K, Oishi A, Yoshimura N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/71dda01cf6804327843c9fbf907c884a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:71dda01cf6804327843c9fbf907c884a
record_format	dspace
spelling	oai:doaj.org-article:71dda01cf6804327843c9fbf907c884a2021-12-02T04:05:59ZChoroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization1177-54671177-5483https://doaj.org/article/71dda01cf6804327843c9fbf907c884a2012-05-01T00:00:00Zhttp://www.dovepress.com/choroidal-thickness-after-intravitreal-ranibizumab-injections-for-chor-a10000https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Abdallah A Ellabban, Akitaka Tsujikawa, Ken Ogino, Sotaro Ooto, Kenji Yamashiro, Akio Oishi, Nagahisa YoshimuraDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanPurpose: To study changes in choroidal thickness with ranibizumab treatment for choroidal neovascularization (CNV).Design: Prospective case series.Methods: This prospective study consisted of 60 CNV-affected eyes of 60 patients treated with intravitreal injections of ranibizumab using an on-demand protocol after an initial loading phase. The eyes studied included 20 with age-related macular degeneration (AMD), 20 with polypoidal choroidal vasculopathy (PCV), and 20 with myopic CNV. In the eyes with AMD and PCV, choroidal thickness at the fovea was measured with optical coherence tomography using enhanced depth imaging. In eyes with myopic CNV, the choroidal thickness was measured using standard optical coherence tomography without the enhanced depth imaging technique.Results: With ranibizumab treatment, central retinal thickness decreased significantly (P &lt; 0.001) and visual acuity improved significantly (P &lt; 0.001). However, central choroidal thickness (167.2 &plusmn; 108.3 &micro;m) showed no significant change at 1 month after the loading phase (165.2 &plusmn; 107.8 &micro;m, P = 0.120) or at final examination (164.8 &plusmn; 107.7 &micro;m, P = 0.115). At baseline, central retinal thickness in eyes with AMD was significantly greater that those with PCV (P = 0.005) or high myopia (P = 0.029). However, central choroidal thickness in eyes with myopic CNV was significantly thinner than in eyes with AMD (P &lt; 0.001) or PCV (P &lt; 0.001). In each type of disease, there was no significant change in central choroidal thickness with ranibizumab treatment.Conclusion: The effect of ranibizumab on the choroidal thickness is minimal, if any.Keywords: choroidal thickness, ranibizumab, optical coherence tomographyEllabban AATsujikawa AOgino KOoto SYamashiro KOishi AYoshimura NDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 837-844 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Ellabban AA Tsujikawa A Ogino K Ooto S Yamashiro K Oishi A Yoshimura N Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
description	Abdallah A Ellabban, Akitaka Tsujikawa, Ken Ogino, Sotaro Ooto, Kenji Yamashiro, Akio Oishi, Nagahisa YoshimuraDepartment of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, JapanPurpose: To study changes in choroidal thickness with ranibizumab treatment for choroidal neovascularization (CNV).Design: Prospective case series.Methods: This prospective study consisted of 60 CNV-affected eyes of 60 patients treated with intravitreal injections of ranibizumab using an on-demand protocol after an initial loading phase. The eyes studied included 20 with age-related macular degeneration (AMD), 20 with polypoidal choroidal vasculopathy (PCV), and 20 with myopic CNV. In the eyes with AMD and PCV, choroidal thickness at the fovea was measured with optical coherence tomography using enhanced depth imaging. In eyes with myopic CNV, the choroidal thickness was measured using standard optical coherence tomography without the enhanced depth imaging technique.Results: With ranibizumab treatment, central retinal thickness decreased significantly (P &lt; 0.001) and visual acuity improved significantly (P &lt; 0.001). However, central choroidal thickness (167.2 &plusmn; 108.3 &micro;m) showed no significant change at 1 month after the loading phase (165.2 &plusmn; 107.8 &micro;m, P = 0.120) or at final examination (164.8 &plusmn; 107.7 &micro;m, P = 0.115). At baseline, central retinal thickness in eyes with AMD was significantly greater that those with PCV (P = 0.005) or high myopia (P = 0.029). However, central choroidal thickness in eyes with myopic CNV was significantly thinner than in eyes with AMD (P &lt; 0.001) or PCV (P &lt; 0.001). In each type of disease, there was no significant change in central choroidal thickness with ranibizumab treatment.Conclusion: The effect of ranibizumab on the choroidal thickness is minimal, if any.Keywords: choroidal thickness, ranibizumab, optical coherence tomography
format	article
author	Ellabban AA Tsujikawa A Ogino K Ooto S Yamashiro K Oishi A Yoshimura N
author_facet	Ellabban AA Tsujikawa A Ogino K Ooto S Yamashiro K Oishi A Yoshimura N
author_sort	Ellabban AA
title	Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
title_short	Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
title_full	Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
title_fullStr	Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
title_full_unstemmed	Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
title_sort	choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/71dda01cf6804327843c9fbf907c884a
work_keys_str_mv	AT ellabbanaa choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization AT tsujikawaa choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization AT oginok choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization AT ootos choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization AT yamashirok choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization AT oishia choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization AT yoshimuran choroidalthicknessafterintravitrealranibizumabinjectionsforchoroidalneovascularization
_version_	1718401435389919232

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

Ejemplares similares